Journal article

Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization

Ben Zhang, Xiao-Ou Shu, Ryan J Delahanty, Chenjie Zeng, Kyriaki Michailidou, Manjeet K Bolla, Qin Wang, Joe Dennis, Wanqing Wen, Jirong Long, Chun Li, Alison M Dunning, Jenny Chang-Claude, Mitul Shah, Barbara J Perkins, Kamila Czene, Hatef Darabi, Mikael Eriksson, Stig E Bojesen, Borge G Nordestgaard Show all

Journal of the National Cancer Institute | OXFORD UNIV PRESS INC | Published : 2015

Grants

Awarded by US National Institutes of Health (NIH)


Awarded by European Community's Seventh Framework Programme


Awarded by European Community's Seventh Framework Programme (COGS)


Awarded by Cancer Research UK (CR-UK)


Awarded by National Institutes of Health


Awarded by Post-Cancer GWAS initiative (GAME-ON initiative)


Awarded by Department of Defence


Awarded by National Cancer Institute (NCI)


Awarded by National Cancer Institute


Awarded by Dutch Cancer Society


Awarded by BBMRI-NL - Dutch government


Awarded by CR-UK


Awarded by European Union European Cooperation in Science and Technology (COST) programme


Awarded by Fondo de Investigacion Sanitario


Awarded by California Breast Cancer Research Fund


Awarded by Lon V Smith Foundation


Awarded by Deutsche Krebshilfe


Awarded by Federal Ministry of Education and Research (BMBF) Germany


Awarded by Academy of Finland


Awarded by NHMRC


Awarded by United States Army Medical Research and Materiel Command


Awarded by Stichting tegen Kanker


Awarded by Deutsche Krebshilfe e.V.


Awarded by NIH


Awarded by NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer


Awarded by Australian NHMRC


Awarded by Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program


Awarded by Ministry of Economic Development, Innovation and Export Trade


Awarded by Norwegian Research council


Awarded by FUGE-NFR


Awarded by Biobanking and Biomolecular Resources Research Infrastructure


Awarded by Yorkshire Cancer Research


Awarded by Cancer Research UK


Awarded by Specialized Program of Research Excellence (SPORE) in Breast Cancer


Awarded by Hellenic Cooperative Oncology Group research grant


Awarded by DBBR (a CCSG Share Resource by National Institutes of Health)



Funding Acknowledgements

The work for this project at Vanderbilt University was supported primarily by US National Institutes of Health (NIH) grant R37CA070867 and funds from Ingram Professorship and Anne Potter Wilson endowments. This work was partly supported by the European Community's Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2-2009-223175) (Collaborative Oncological Gene-Environment Study [COGS]). Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement No. 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (CR-UK; C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692), the National Institutes of Health (CA128978), and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.The Genetic Associations and Mechanisms in Oncology Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (GAME-ON DRIVE) Consortium was supported by National Cancer Institute (NCI) Grant number U19 CA148065. The work of the Breast Cancer Family Registry (BCFR) included in DRIVE was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government or the BCFR.The Australian Breast Cancer Family Study (ABCFS), NC-BCFR, and Ontario Familial Breast Cancer Registry (OFBCR) work was supported by grant UM1 CA164920 from the National Cancer Institute. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia), and the Victorian Breast Cancer Research Consortium. John. L. Hopper is a National Health and Medical Research Council (NHMRC) Australia Fellow and a Victorian Breast Cancer Research Consortium Group Leader. Melissa C. Southey is an NHMRC Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader. The Amsterdam Breast Cancer Study (ABCS) study was supported by the Dutch Cancer Society (grants NKI 2007-3839; 2009 4363); BBMRI-NL, which is a Research Infrastructure financed by the Dutch government (NWO 184.021.007); and the Dutch National Genomics Initiative. The work of the Bavarian Breast Cancer Cases and Controls (BBCC) was partly funded by ELAN-Fond of the University Hospital of Erlangen. The Bavarian British Breast Cancer Study (BBCS) is funded by Cancer Research UK and Breakthrough Breast Cancer and acknowledges National Health Service (NHS) funding to the National Institute for Health Research (NIHR) Biomedical Research Centre, and the National Cancer Research Network (NCRN). The Breast Cancer Association Consortium (BCAC) is funded by CR-UK (C1287/A10118 and C1287/A12014). Meetings of BCAC have been funded by the European Union European Cooperation in Science and Technology (COST) programme (BM0606). Douglas F. Easton is a Principal Research Fellow of CR-UK. In the Breast Cancer in Galway Genetic Study (BIGGS), Elinor Sawyer is supported by NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, United Kingdom. Ian Tomlinson is supported by the Oxford Biomedical Research Centre. The Breast Cancer Study of the University of Heidelberg (BSUCH) study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society, and the German Cancer Research Center (DKFZ).The CECILE Breast Cancer Study was funded by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Ligue contre le Cancer Grand Ouest, Agence Nationale de Securite Sanitaire (ANSES), Agence Nationale de la Recherche (ANR). The Copenhagen General Population Study (CGPS) was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev Hospital. The Spanish National Cancer Centre Breast Cancer Study (CNIO-BCS) was supported by the Genome Spain Foundation, the Red Tematica de Investigacion Cooperativa en Cancer, and grants from the Asociacion Espanola Contra el Cancer and the Fondo de Investigacion Sanitario (PI11/00923 and PI081120). The Human Genotyping-CEGEN Unit (CNIO) is supported by the Instituto de Salud Carlos III. The California Teachers Study (CTS) was initially supported by the California Breast Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500) and is currently funded through the National Institutes of Health (R01 CA77398). Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. Hoda Anton-Culver receives support from the Lon V Smith Foundation (LVS39420). The Esther Breast Cancer Study (ESTHER) study was supported by a grant from the Baden Wurttemberg Ministry of Science, Research and Arts. Additional case patients were recruited in the context of the Verlauf der diagnostischen Abklarung study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). The German Consortium for Hereditary Breast & Ovarian Cancer (GC-HBOC) was supported by Deutsche Krebshilfe (107 352). The Gene Environment Interaction and Breast Cancer in Germany (GENICA) was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0, and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. The Helsinki Breast Cancer Study (HEBCS) was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, the Nordic Cancer Union, and the Sigrid Juselius Foundation. The Hannover-Minsk Breast Cancer Study (HMBCS) was supported by a grant from the Friends of Hannover Medical School and by the Rudolf Bartling Foundation. Financial support for Karolinska Breast Cancer Study (KARBAC) was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V Jubilee Foundation and and Bert von Kantzows Foundation. The Kuopio Breast Cancer Project (KBCP) was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, and by the strategic funding of the University of Eastern Finland.The Kathleen Cuningham Foundation Consortium for research into Familial Breast Cancer (kConFab) is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and NHMRC, the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. The kConFab Clinical Follow Up Study was funded by the NHMRC (145684, 288704, 454508). Financial support for the Australian Ovarian Cancer Study (AOCS) was provided by the United States Army Medical Research and Materiel Command (DAMD17-01-1-0729), the Cancer Council of Tasmania and Cancer Foundation of Western Australia, and the NHMRC [199600]. Georgia Chenevix-Trench and Penelope M. Webb are supported by the NHMRC. Leuven Multidisciplinary Breast Centre (LMBC) is supported by the 'Stichting tegen Kanker' (232-2008 and 196-2010). Diether Lambrechts is supported by the Flemish Fund for Scientific Research and the KULPFV/10/016-SymBioSysII. The Mammary Carcinoma Risk Factor Investigation (MARIE) study was supported by the Deutsche Krebshilfe e.V. (70-2892-BR I, 106332, 108253, 10841), the Hamburg Cancer Society, the German Cancer Research Center, and the Federal Ministry of Education and Research (BMBF) Germany (01KH0402). Milan Breast Cancer Study Group (MBCSG) is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects "5x1000"). The Mayo Clinic Breast Cancer Study (MCBCS) Clinic Breast Cancer Study (MCBCS) was supported by the NIH grants CA128978, CA116167, CA176785, an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), the Breast Cancer Research Foundation, and a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation. Melbourne Collaborative Cohort Study (MCCS) cohort recruitment in the study was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553, and 504711 and by infrastructure provided by Cancer Council Victoria. The Multi-ethnic Cohort (MEC) was support by NIH grants CA63464, CA54281, CA098758, and CA132839. The work of Montreal Gene-Environment Breast Cancer Study (MTLGEBCS) was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program (grant number CRN-87521), and the Ministry of Economic Development, Innovation and Export Trade (grant number PSR-SIIRI-701). The Norwegian Breast Cancer Study was supported by grants from the Norwegian Research council, 155218/V40, 175240/S10 to ALBD, FUGE-NFR 181600/V11 to VNK and a Swizz Bridge Award to ALBD. The Oulu Breast Cancer Study (OBCS) was supported by research grants from the Finnish Cancer Foundation, the Academy of Finland, the University of Oulu, and the Oulu University Hospital. The OFBCR was supported by grant UM1 CA164920 from the National Cancer Institute. The Leiden University Medical Centre Breast Cancer Study (ORIGO) study was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16).The NCI Polish Breast Cancer Study (PBCS) was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services. The Karolinska Mammography Project for Risk Prediction of Breast Cancer - prevalent cases (pKARMA) study was supported by Marit and Hans Rausings Initiative Against Breast Cancer. The Rotterdam Breast Cancer Study (RBCS) was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The Singapore and Sweden Breast Cancer Study (SASBAC) study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health, and the Susan G. Komen Breast Cancer Foundation. The Sheffield Breast Cancer Study (SBCS) was supported by Yorkshire Cancer Research S295, S299, and S305PA. Study of Epidemiology and Risk factors in Cancer Heredity (SEARCH) is funded by a program grant from Cancer Research UK [C490/A10124] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. Stadtisches Klinikum Karlsruhe Deutsches Krebsforschungszentrum Study (SKKDKFZS) is supported by the DKFZ. The IHCC-Szczecin Breast Cancer Study (SZBCS) was supported by Grant PBZ_KBN_122/P05/2004. The Triple Negative Breast Cancer Consortium Study (TNBCC) was supported by: a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a grant from the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation, the Stefanie Spielman Breast Cancer fund and the OSU Comprehensive Cancer Center, DBBR (a CCSG Share Resource by National Institutes of Health Grant P30 CA016056), the Hellenic Cooperative Oncology Group research grant (HR R_BG/04) and the Greek General Secretary for Research and Technology (GSRT) Program, Research Excellence II, the European Union (European Social Fund), and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF), ARISTEIA. The UK Breakthrough Generations Study (UKBGS) is funded by Breakthrough Breast Cancer and the Institute of Cancer Research (ICR). ICR acknowledges NHS funding to the NIHR Biomedical Research Centre.